Evidence map›Paper›PMID 38733420›Full record

ReviewFamilial cancer2024

The response of pancreatic acinar cell carcinoma to platinum and olaparib therapy in a germline BRCA2 variant carrier: case report and literature review.

Hiroyuki Matsubayashi, Akiko Todaka, Takahiro Tsushima, Yoshimi Kiyozumi, Rina Harada, Eiko Ishihara, Satomi Higashigawa, Nobuyuki Ohike, Hiroki Sakamoto, Junya Sato and 3 more

Abstract readCase ReportsReview
PubMed Publisher
In one paragraph

Review in Familial cancer, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Review
  3. Metastatic pancreatic acinar cell carcinoma withJournal of gastrointestinal oncology · 2025
    Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Hiroyuki MatsubayashiDivision of Genetic Medicine Promotion, Shizuoka Cancer Center, 1007, Shimonagakubo, Nagaizumi, Suntogun, Shizuoka, 411-8777, Japan. h.matsubayashi@scchr.jp.
Akiko TodakaDivision of Medical Oncology and Hematology, Faculty of Medicine, Oita University, Oita, Japan.
Takahiro TsushimaDivision of GI Oncology, Shizuoka Cancer Center, Shizuoka, Japan.
Yoshimi KiyozumiDivision of Genetic Medicine Promotion, Shizuoka Cancer Center, 1007, Shimonagakubo, Nagaizumi, Suntogun, Shizuoka, 411-8777, Japan.
Rina HaradaDivision of Genetic Medicine Promotion, Shizuoka Cancer Center, 1007, Shimonagakubo, Nagaizumi, Suntogun, Shizuoka, 411-8777, Japan.
Eiko IshiharaDivision of Genetic Medicine Promotion, Shizuoka Cancer Center, 1007, Shimonagakubo, Nagaizumi, Suntogun, Shizuoka, 411-8777, Japan.
Satomi HigashigawaDivision of Genetic Medicine Promotion, Shizuoka Cancer Center, 1007, Shimonagakubo, Nagaizumi, Suntogun, Shizuoka, 411-8777, Japan.
Nobuyuki OhikeDivision of Pathology, Shizuoka Cancer Center, Shizuoka, Japan.
Hiroki SakamotoDivision of Endoscopy, Shizuoka Cancer Center, Shizuoka, Japan.
Junya SatoDivision of Endoscopy, Shizuoka Cancer Center, Shizuoka, Japan.
Hirotoshi IshiwatariDivision of Endoscopy, Shizuoka Cancer Center, Shizuoka, Japan.
Teichi SugiuraHepato-Biliary-Pancreatic Surgery of Shizuoka Cancer Center, Shizuoka, Japan.
Katsuhiko UesakaHepato-Biliary-Pancreatic Surgery of Shizuoka Cancer Center, Shizuoka, Japan.

Funding

JSPS KAKENHI 19K19372
6 · The paper itself

Abstract

A 73-year-old Japanese man with a history of distal biliary cancer treated by pancreatoduodenectomy developed pancreatic acinar cell carcinoma (PACC) treated by remnant pancreatectomy and adjuvant chemotherapy. Thirteen months after surgery, multiple liver metastases developed and FOLFOX chemotherapy was initiated. Based on the PACC diagnosis and a positive family history for breast and ovarian cancer genetic testing was performed which revealed a pathogenic germline BRCA2 variant (c.8629G > T, p.Glu2877Ter). Olaparib therapy was initiated and the metastases responded well (partial response). PACC is a BRCA2-associated cancer which may respond well to PARP inhibitors.

Indexed as

Antineoplastic Combined Chemotherapy ProtocolsBRCA2 ProteinCarcinoma, Acinar CellGerm-Line MutationPancreatic NeoplasmsPhthalazinesPiperazinesAgedFluorouracilHumansLeucovorinLiver NeoplasmsMaleOrganoplatinum CompoundsPoly(ADP-ribose) Polymerase InhibitorsBRCA2 ProteinBRCA2 protein, humanFluorouracilLeucovorinolaparibOrganoplatinum CompoundsPhthalazinesPiperazinesPoly(ADP-ribose) Polymerase InhibitorsBRCAGenetic testingPancreatic acinar cell carcinomaPARP inhibitors

Identifiers

PMID38733420

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.